Histopathologic image of pulmonary invasive aspergillosis. Credit: KGH.

Pfizer has signed an agreement with Switzerland-based Basilea Pharmaceutica for the exclusive development and commercialisation rights to Cresemba (isavuconazole) in China and the Asia Pacific region.

Developed to treat adults with invasive aspergillosis and mucormycosis, Cresemba is an intravenous (IV), oral azole anti-fungal and active agent of prodrug isavuconazonium sulfate.

The firms previously signed an agreement in July, under which Pfizer obtained exclusive commercialisation rights for Cresemba in Europe, except Nordic countries.

Pfizer is currently marketing the drug in Austria, France, Germany, Italy, UK and Spain, and plans to launch in other countries over time.

The latest deal provides the firm with rights to develop, distribute and commercialise Cresemba in China and 16 Asia Pacific countries, except Japan.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Pfizer is currently marketing the drug in Austria, France, Germany, Italy, UK and Spain, and plans to launch in other countries over time.”

Pfizer APAC, Greater China and Global Brands global president Suneet Varma said: “We believe our extensive geographic footprint in APAC and China, together with our expertise in successfully commercialising innovative medicines, will help enable us to continue to address the unmet medical needs of patients, especially in the area of anti-infectives.”

The US Food and Drug Administration (FDA) approved Cresemba in March 2015 for invasive aspergillosis and mucormycosis treatment in patients aged 18 and above.

The drug received the European centralised marketing authorisation in October of the same year to treat adults with invasive aspergillosis and for mucormycosis patients who cannot use amphotericin B.

It has orphan drug designation in both countries, and is commercialised by Astellas Pharma in the US.